Sanofi’s Sarclisa gets approved as a first-line option for some patients newly diagnosed with multiple myeloma

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Tennessee Medical Board Refuses to Enforce New IMG Law

Members of the Tennessee Board of Medical Examiners felt they were locked in an impossibly tough spot. They had to choose between defying a new

September 7, 2024

Formosa and Tabuk sign deal for ophthalmic suspension

The formulation offers a convenient dosing regimen, requiring administration only twice daily for 14 days. Credit: megaflopp / Shutterstock.com. Formosa Pharmaceuticals has announced an exclusive

May 10, 2024

Job strain and effort-reward imbalance linked to higher risk of atrial fibrillation

Work-related stress caused by job strain and an imbalance between efforts applied vs. rewards received may increase the risk of developing atrial fibrillation, according to

August 14, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.